According to Irina Kurashkina, the Deputy Head of Division for Sectoral Planning and Strategic Development at the Department of Pharmaceutical and Medical Industry Development, in H1 2017, the volume of Russian pharmaceutical market was 702 billion rubles.
In monetary terms, it grew by 11.4% compared to the same period of 2016. The share of Russian-made medicines is 61.6% in terms of packages and 30% in monetary terms. In six month, the output increased by 13% to 187.6 billion rubles. Today, the Russian manufacturers cover 83% of needs in medicinal products from the list of vital and essential drugs. By 2020, this figure is expected to reach 90%.
Pharma 2020, a state program, provides for production of 132 import-substituting drugs, including 62 that are already registered with the support of the Ministry of Industry and Trade. In addition, two innovative drug have been registered with the support of the Ministry at the plants of R-Pharm (narlaprevir) and ChemRar (gosogliptin).
The Ministry of Industry and Trade also allocated subsidies in amount 326.8 million rubles for conducting the 41st clinical trials. For example, Pharmasyntez received about 100 million rubles for these purposes, said Irina Kurashkina.
According to her, eight projects received 187 million rubles of subsidies for payments under equipment leasing contracts, pilot production of pharmaceutical substances, and validation series. Another 11 projects received 137.8 million rubles to support the creation of bio-targets. In 2015 – 2017, 14 projects in the pharmaceutical industry were supported in collaboration with the Industrial Development Fund (IDF). The total amount of loans reached 4.7 billion rubles.
The Ministry is actively promoting the Special Investment Contracts (SPIC), said Irina Kurashkina. For example, the first contract with AstraZeneca Russia is in its final stage of approval; and the signing of another six contracts for 7 billion rubles is expected in the near future.